164 related articles for article (PubMed ID: 36495155)
1. Association between Serum Biomarkers with Postoperative Complications and Delay of Adjuvant Chemotherapy Initiation in Ovarian Cancer Patients Undergoing Primary Cytoreductive Surgery: A Pilot Study.
Ade CJ; Dockery L; Walter AC; Benbrook DM; Vesely SK; Hammond ST; Moore KN; Holman LL
Nutr Cancer; 2023; 75(2):662-669. PubMed ID: 36495155
[TBL] [Abstract][Full Text] [Related]
2. Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced Ovarian Cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery.
Castro BGR; Dos Reis R; Cintra GF; Sousa MMA; Vieira MA; Andrade CEMDC
Int J Gynecol Cancer; 2018 Oct; 28(8):1520-1528. PubMed ID: 30036229
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
[TBL] [Abstract][Full Text] [Related]
4. Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study.
Miralpeix E; Sole-Sedeno JM; Rodriguez-Cosmen C; Taus A; Muns MD; Fabregó B; Mancebo G
World J Surg Oncol; 2022 Feb; 20(1):46. PubMed ID: 35197061
[TBL] [Abstract][Full Text] [Related]
5. Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
Nica A; Covens A; Parra-Herran C; May T
Gynecol Oncol; 2020 Sep; 158(3):622-630. PubMed ID: 32561124
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
7. Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
Praiss AM; Zhou Q; Iasonos A; Moukarzel L; Dessources K; Soldan K; Su K; Sonoda Y; Roche KL; Gardner GJ; Troso-Sandoval T; Tew WP; Grisham RN; Chi DS; O'Cearbhaill RE; Zivanovic O
Gynecol Oncol; 2023 Apr; 171():23-30. PubMed ID: 36804618
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal ropivacaine reduces time interval to initiation of chemotherapy after surgery for advanced ovarian cancer: randomised controlled double-blind pilot study.
Hayden JM; Oras J; Block L; Thörn SE; Palmqvist C; Salehi S; Nordstrom JL; Gupta A
Br J Anaesth; 2020 May; 124(5):562-570. PubMed ID: 32172954
[TBL] [Abstract][Full Text] [Related]
9. Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery.
Nasioudis D; Wang X; Dhillon G; Latif N; Ko EM; Giuntoli RL; Gershenson D; Fader A; Carey M; Simpkins F
Int J Gynecol Cancer; 2023 Dec; 33(12):1906-1912. PubMed ID: 37879909
[TBL] [Abstract][Full Text] [Related]
10. National trends in bowel and upper abdominal procedures in ovarian cancer surgery.
Dottino JA; He W; Sun CC; Zhao H; Fu S; Rauh-Hain JA; Suidan RS; Lu KH; Giordano SH; Meyer LA
Int J Gynecol Cancer; 2020 Aug; 30(8):1195-1202. PubMed ID: 32616627
[TBL] [Abstract][Full Text] [Related]
11. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer.
Wright JD; Herzog TJ; Neugut AI; Burke WM; Lu YS; Lewin SN; Hershman DL
Obstet Gynecol; 2012 Oct; 120(4):871-81. PubMed ID: 22996105
[TBL] [Abstract][Full Text] [Related]
12. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
13. The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study.
Lee YY; Kim SR; Kollara A; Brown T; May T
J Gynecol Oncol; 2022 Nov; 33(6):e76. PubMed ID: 36047378
[TBL] [Abstract][Full Text] [Related]
14. Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
Li S; Bercow AS; Falzone M; Kalyanaraman R; Worley MJ; Feltmate CM; Pelletier A; Elias KM
Gynecol Oncol; 2021 Aug; 162(2):353-359. PubMed ID: 34092412
[TBL] [Abstract][Full Text] [Related]
15. Loss of skeletal muscle density during neoadjuvant chemotherapy in older women with advanced stage ovarian cancer is associated with postoperative complications.
van der Zanden V; van Soolingen NJ; Viddeleer AR; Trum JW; Amant F; Mourits MJE; Portielje JEA; Baalbergen A; Souwer ETD; van Munster BC
Eur J Surg Oncol; 2022 Apr; 48(4):896-902. PubMed ID: 34756760
[TBL] [Abstract][Full Text] [Related]
16. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
17. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
[TBL] [Abstract][Full Text] [Related]
18. Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer.
Sanders BE; Saharti S; Laus K; Bristow RE; Eskander RN
J Obstet Gynaecol; 2021 Aug; 41(6):956-961. PubMed ID: 33228421
[TBL] [Abstract][Full Text] [Related]
19. Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
Baldewpersad Tewarie NMS; van Driel WJ; van Ham M; Wouters MW; Kruitwagen R;
Gynecol Oncol; 2021 Aug; 162(2):331-338. PubMed ID: 34147284
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis.
Kengsakul M; Nieuwenhuyzen-de Boer GM; Udomkarnjananun S; Kerr SJ; Niehot CD; van Beekhuizen HJ
J Gynecol Oncol; 2022 Jul; 33(4):e53. PubMed ID: 35712967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
